Company
Alchemab Therapeutics, Ltd.
Pioneering the next generation of antibody therapeutics for hard to treat diseases
Also known as Alchemab Therapeutics
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- London, United Kingdom
- Customers
- business customers
- Legal name
- Alchemab Therapeutics Ltd
- alchemab.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires. The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.
Funding snapshot
- Total raised
- $34.6MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A, $34M2026-07-09
Funding rounds
- Series A
- $34M2026-07-09, Company stated
- Grant
- $595K2024-06-06, Company stated
Loading relationship preview